ConvaTec stock holds steady as half-year 2026 margins and guidance stay on track

ConvaTec Group PLC stock (ISIN GB00BD3VFW73) traded at around 221.00 pence on the London Stock Exchange on September 10, 2026, close to levels seen in recent sessions as investors continue to digest the company’s half-year 2026 results and guidance.

Half-year 2026 figures support steady outlook

According to MarketBeat on August 4, 2026, ConvaTec reported 5 percent organic revenue growth in the first half of 2026, excluding the InnovaMatrix product, and maintained its financial targets for the year. In the same half-year 2026 update, the company achieved an operating margin of 21.2 percent, which was described as down 10 basis points from the prior-year period but up 50 basis points on a constant-currency basis, giving investors a detailed picture of both reported and underlying profitability.

The half-year 2026 results also showed adjusted earnings per share rising by 6 percent compared with the first half of the previous year, while management reaffirmed its expectation for double-digit EPS growth for the full year 2026, highlighting a clear quantified improvement in earnings alongside the revenue and margin trends.MarketBeat noted that management continued to expect stronger second-half growth, particularly in the Infusion Care segment, which should support the margin trajectory.

InnovaMatrix remains a headwind but guidance intact

As MarketBeat reports, InnovaMatrix, ConvaTec’s skin-substitute product, generated only GBP 2.5 million in sales in the first half of 2026, significantly less than earlier expectations and prompting a GBP 69 million non-cash impairment charge. The company now expects InnovaMatrix to contribute between GBP 5 million and GBP 10 million in revenue for the full year 2026, and this revised outlook is estimated to create a roughly 2.5 percent headwind to annual group revenue growth, a quantified drag that investors need to factor into their models.

Despite the InnovaMatrix shortfall and impairment, MarketBeat highlights that ConvaTec maintained its 2026 targets, including the expectation that operating margin will reach about 25 percent in the second half of 2026 and stay in the mid-20 percent range from 2027 onward. For shareholders, the message is that the core business and margin strategy remain intact even as InnovaMatrix weighs on reported growth, and the quantified margin guidance gives a clear benchmark for evaluating execution in the coming quarters.

Analyst consensus and share price context

Analyst consensus data compiled by MarketScreener on September 10, 2026 show an average target price of 2.994 dollars for ConvaTec’s stock, with a high target of 4.960 dollars and a low target of 3.049 dollars, underlining that analysts see upside potential from current trading levels on the home market when converted into dollar terms. While individual rating changes are not detailed in the consensus snapshot, the spread between the average and highest target price suggests that some covering analysts expect materially higher valuation if the company delivers on its margin and growth plans.

On the price side, LSE data referenced by Yahoo Finance show ConvaTec’s CTEC.L shares at 221.00 pence with a modest daily move of about minus 0.18 percent as of September 10, 2026, while an intraday quote snapshot from Investing.com UK lists ConvaTec Group at 220.80 pence, down 0.09 percent on the day with trading volume of around 457,840 shares. These figures place ConvaTec stock in a relatively tight trading range while investors balance the positive margin guidance against the InnovaMatrix revenue headwinds and impairment charge.

ConvaTec stock price level

ConvaTec Group PLC stock closed around 221.00 pence on the London Stock Exchange on September 10, 2026, with the home listing on the LSE serving as the primary reference for the share price in sterling terms.

More news and analyses on ConvaTec stock